Choose page section to go to:

Key Performance Indicators

Access to Medicines

Global programs and commercial transactions to increase access to medicines in emerging markets^1,²


2014	14
2015	19
2016	18
2017	17
2018	17

Top 21 global burdens of disease addressed by products and pipeline³


2014	18
2015	18
2016	19
2017	19
2018	16

Overview³

We currently have 285 active programs for launched medicines in markets.
This covers 53 countries.
Of these, 16 programs cover multiple therapies while the rest are product specific.
In total, these cover 104 different products in our portfolio.

Program/commercial transaction defined as a Pfizer investment or dedicated contract of over $250,000 with a national government or procurement agency, multilateral organization, non-governmental organization, private institution or aid agency. Represents multi-country initiatives only and does not include numerous local initiatives to address access.
Pfizer Foundation programs represent aggregate investment in program areas with several NGO partners.
As defined by the World Health Organization. Burdens of illness not addressed include unintentional injuries, transport injuries, malaria & neglected tropical diseases, self-harm, and interpersonal violence.
The number of patient access programs with pricing tailored to different patient segments (for at least one product), allowing access for more patients.

Top Ten Medicines and Vaccines by Revenues in 2018

1	$5,802 million Prevnar 13 / Prevenar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein])
2	$4,969 million¹ Lyrica^© (pregabalin)
3	$4,188 million Ibrance^© (palbociclib)
4	$3,434 million² Eliquis ^© (apixaban)
5	$2,122 million³ Enbrel (Etanercept)
6	$2,062 million Lipitor^© (atorvastatin)
7	$1,774 million Xeljanz^© (tofacitinib)
8	$1,085 million Chantix^© (varenicline)
9	$1,049 million Sutent^© (sunitinib malate)
10	$1,024 million Norvasc^® (amlodipine besylate)

Total Revenue (PIH+PEH)
Alliance Revenue & Direct Sales
Outside U.S. and Canada

Colleagues¹

Injuries Per 100 Colleagues

Total injury rate in 2018 was 24% lower than in 2017


2015	0.48
2016	0.39
2017	0.59
2018	0.45

Progress on Our 2020 Environmental Sustainability Goals²

Greenhouse Gas Emissions

Total scope 1 and 2 GHG emissions
In million metric tons CO2EQ

GHG emissions in 2018 were 1.8% higher than in 2017

2020 Goals vs Baseline:
Decrease by 20%


2012	2.15
2015	1.92
2016	1.76
2017	1.67
2018	1.70

Baseline

Waste Disposed

Total hazardous and non-hazardous waste in thousand metric tons

Total waste disposed in 2018 was 3% lower than in 2017

2020 Goals vs Baseline:
Decrease by 15%


2012	126.12
2015	124.86
2016	106.53
2017	100.07
2018	97.13

Baseline

Water Withdrawal

Excluding non-contact cooling water in million cubic meters

Total water withdrawal (excluding non-contact cooling water) in 2018 5% higher than in 2017

2020 Goals vs Baseline:
Decrease by 5%


2012	18.87
2015	16.73
2016	16.64
2017	15.51
2018	16.33

Baseline

Supply Chain Environmental Sustainability Goal³

	2020 Goal	2018	2017	2016
Key suppliers supporting Pfizer's supplier code of conduct	100%	88%	83%	79%
Key suppliers aligning with Pharmaceutical Supply Chain Initiative (PSCI) principles	100%	90%	66%	35%
Key suppliers managing their environmental impacts	100%	85%	84%	76%
Key suppliers with reduction goals for GHG, waste disposal and water withdrawal	90%	53%	53%	51%

Sadly we had one road traffic related fatality in 2018. Refer to the 2017 Annual Review for explanation of the injury rate increase noted in 2017. Factors leading to this increase were not repeated in 2018. The primary cause of injuries and illnesses recorded in 2018 related to slips, trips and falls, and ergonomics.
Applies to facilities within Pfizer's operational control as compared with a 2012 baseline. Data are baseline adjusted, reported absolute, using reporting boundaries per the WRI GHG Protocol. The 2012–2017 GHG data was independently verified to the limited assurance level. The verification of the 2018 GHG data will be completed in 2019. In both 2017 and 2018 we met our 2020 goals for greenhouse gas (GHG) emissions, waste reductions, and water conservation. While we expect some fluctuations in our environmental sustainability performance due to business changes in 2019 and 2020, we are confident that we are in a position to develop new goals in 2019 that align with the strategic objectives of Pfizer's three business units. Through 2020 and beyond we will continue to focus on emission and resource reduction projects. Expanded environmental reporting will be posted on www.pfizer.com later in 2019.
Key suppliers currently include 126 major contributors to our external environmental footprint, strategic collaborators with Worldwide Research and Development, and those suppliers we anticipate having continued involvement with. Key suppliers represent only a portion of Pfizer's overall supply chains for goods and services and we continue to look for opportunities to broaden our influence on our supply base.